Firdapse cardiac safety study hits endpoint; LEMS data next
By Marie Powers
Wednesday, January 8, 2014
The first formal human cardiac safety study of Firdapse (amifampridine phosphate) met its pre-specified endpoint, demonstrating no effect on heart rate or cardiac depolarization when administered at and above therapeutic levels. The findings boosted prospects for Catalyst Pharmaceutical Partners Inc., who jointly funded the study with Biomarin Pharmaceutical Inc., which conducted the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.